VERU · XBRL financial data

Veru financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (VERU's year ends in late September)

In thousands of dollars	FY 2020Sep 30, 2020	FY 2021Sep 30, 2021	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025†Sep 30, 2025
Revenue	42,592	61,260	39,354	16,297	—	—
Revenue from contracts with customers	42,592	61,260	39,354	16,297	16,886	—
Cost of goods and services sold	11,805	13,332	8,763	8,731	11,032	—
Gross profit	30,787	47,927	30,591	7,566	5,854	—
Research and development	16,935	32,694	70,646	51,202	12,808	15,588
Selling, general and administrative	14,498	20,670	43,169	48,058	31,184	—
General and administrative	—	—	—	—	24,610	19,943
Total operating expenses	45,534	53,365	113,815	107,072	43,992	35,531
Operating income (loss)	(14,747)	12,973	(83,224)	(93,782)	(36,915)	(24,751)
Interest expense	4,621	4,886	4,369	2,427	607	—
Other income (expense)	(127)	(152)	496	574	862	768
Income tax expense (benefit)	(1,078)	(3,129)	236	480	725	0
Net income (loss)	(18,974)	7,394	(83,776)	(93,153)	(37,801)	(22,726)
Earnings per share, basic USD per share	(0.28)	0.10	(1.05)	(1.10)	(0.28)	(1.55)
Earnings per share, diluted USD per share	(0.28)	0.09	(1.05)	(1.10)	—	—
Weighted average shares, basic thousands of shares	66,753	76,273	80,123	84,973	134,875	14,646
Weighted average shares, diluted thousands of shares	66,753	83,802	80,123	84,973	—	—

† Share count changed about 1/9 in the period ending 2025-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (VERU's year ends in late September)

In thousands of dollars	FY 2020Sep 30, 2020	FY 2021Sep 30, 2021	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025†Sep 30, 2025
Cash and cash equivalents	—	—	—	9,625	24,916	15,795
Accounts receivable	5,227	8,794	3,551	4,507	3,960	—
Inventory	6,704	5,574	8,619	6,697	4,144	—
Prepaid and other current assets	1,495	851	1,964	1,098	1,783	595
Total current assets	27,015	151,753	104,769	22,933	35,223	18,915
Property and equipment, net	313	593	1,186	1,653	1,285	365
Right-of-use asset	1,352	970	4,787	4,332	3,562	2,746
Goodwill	6,879	6,879	6,879	6,879	6,879	6,879
Total assets	51,544	178,147	136,126	50,023	60,419	29,836
Accounts payable	2,813	3,410	22,003	12,931	3,037	3,121
Total current liabilities	14,727	15,767	41,438	17,811	11,868	7,785
Lease liability, non-current	990	610	4,094	3,634	2,921	2,358
Total liabilities	21,432	25,853	55,287	30,345	28,102	11,503
Accumulated deficit	(89,193)	(81,798)	(165,574)	(256,768)	(294,570)	(317,296)
Total stockholders' equity	30,111	152,294	80,839	19,678	32,317	18,333
Total liabilities and equity	51,544	178,147	136,126	50,023	60,419	29,836
Common shares outstanding (cover page) thousands of shares	70,075	80,030	80,623	93,673	146,384	16,050

† Share count changed about 1/9 in the period ending 2025-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (VERU's year ends in late September)

In thousands of dollars	FY 2020Sep 30, 2020	FY 2021Sep 30, 2021	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025†Sep 30, 2025
Net income (loss)	(18,974)	7,394	(83,776)	(93,153)	(37,801)	(22,726)
Stock-based compensation	2,646	5,050	11,242	17,919	13,644	8,102
Depreciation and amortization	—	—	—	270	268	152
Net cash from operating activities	(1,930)	(15,571)	(47,505)	(88,014)	(21,682)	(30,043)
Purchases of property and equipment	106	377	733	666	158	1
Net cash from investing activities	(106)	14,623	4,267	6,334	146	25,143
Proceeds from issuing common stock	13,400	108,100	—	—	—	—
Net cash from financing activities	9,329	109,718	1,069	11,114	36,827	(4,222)
Net change in cash	7,294	108,771	(42,169)	(70,565)	15,291	(9,122)

† Share count changed about 1/9 in the period ending 2025-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Veru	23,880	not reported	(5,467)*	17.1M	4.4 quarters	Q3 FY26 10-QJun 30, 2026
Lifevantage	14,920	42,377*	4,767*	12.5M	—	Q4 FY26 10-KJun 30, 2026
Whitehawk Therapeutics	85,234	0	(14,529)*	57.0M	13.1 quarters	Q2 FY26 10-QJun 30, 2026
Medicinova	25,416	458	(1,920)*	49.2M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
Corbus Pharmaceuticals Holdings	23,370	not reported	(29,626)*	19.3M	4.0 quarters	Q2 FY26 10-QJun 30, 2026
PDS Biotechnology	5,596	not reported	(2,793)*	56.0M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Sutro Biopharma	54,335	9,839	(38,290)*	16.6M	4.3 quarters	Q2 FY26 10-QJun 30, 2026
iBio	56,395	0*	(6,228)*	64.3M	14.1 quarters	Q4 FY26 10-KJun 30, 2026
Seres Therapeutics	15,594	736	(22,394)*	9.9M	0.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.